JPRN-jRCTs031180364已完成3 期
Efficacy of eicosapentaenoic acid on the prevention of preterm birth in women with cervical shortening - Efficacy of eicosapentaenoic acid on the prevention of preterm birth in women with cervical shortening
agamatsu Takeshi0 个研究点目标入组 98 人开始时间: 2019年3月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 98
研究概览
简要总结
It was shown that the EPA treatment can significantly prevent preterm birth as compared with histrical control. In addition, the significant extension of gestation period, increased birth weight, decreased occurrence of neonatal adverse event, shortened the duration of hospital stays, and the duration of use of a tocolytic agent (ritodrine hydrochloride preparation, magnesium sulfate preparation) were shown in EPA treatment group, compared with histrical control group.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1)Between 24 to 28weeks of gestation, pregnant women with shortened cervix length (< or = 25 mm)
- •or Between 29 to 33weeks of gestation, pregnant women with shortened cervix length (< or = 30 mm)
- •2)Pregnant woman who is at 20 years old or more.(at the time of informed consent)
- •3)Patients who were required to provide written informed consent
排除标准
- •1)Patients with a past history of conization
- •2)Patients who underwent cervical cerclage in current pregnancy
- •3)Premature rupture of the membrane
- •4)fetal anomalies detected by ultrasonography
- •5)Prolapsed fetal membranes
- •6)Chorioamnionitis
- •7)Placenta previa
- •8)Multiple pregnancy
- •9)Painful degeneration of myomas during pregnancy
- •10)Uterine malformations
- •11)Previous medication of eicosapentaenoic acid
- •12)Medication with low-dose aspirin
- •13)Patients judged to be ineligible by attending physician
研究者
相似试验
已完成
不适用
Efficacy of eicosapentaenoic acid on the prevention of preterm birth in women with cervical shorteningthreatened preterm deliveryJPRN-UMIN000027997The University of Tokyo Hospital99
招募中
不适用
Preventive effects of Eicosapentaenoic acid (EPA) on stroke recurrence and a symptom state in chronic stroke patients with dyslipidemia.JPRN-UMIN000006416Tokyo Women's Medical University100
尚未招募
不适用
Prognostic effects of eicosapentaenoic acid (EPA) in patients with atherosclerotic diseasesPatients with atherosclerotic diseasesJPRN-UMIN000012852ational hospital organization Minamiwakayama Medical Center100
招募中
不适用
Evaluation of eicosapentaenoic acid (EPA) for preventing the progression of coronary atherosclerosis and revascularization in patients with dyslipidemia who underwent percutaneous coronary intervention (PCI)Coronary artery disease with dyslipidemiaJPRN-UMIN000003947Kurashiki central Hospital200
尚未招募
4 期
Study of the Efficacy and Safety of EPA in Patients With Type-2 DiabetesDiabetes Type 2Diabetes MellitusHypertriglyceridemiaNCT06129526University of Ioannina450